《业绩》再鼎医药(09688.HK)全年净亏损收窄至2.57亿美元

阿斯达克财经
Feb 28, 2025

再鼎医药(09688.HK) 公布2024年度业绩,按美国公认会计准则,总收入3.99亿美元,按年增加49.6%,主要是艾加莫德持续的强劲表现以及则乐和纽再乐销售收入持续增长。经营亏损由3.67亿美元,收窄至2.82亿美元。亏损净额由3.35亿美元,收窄至2.57亿美元,每股亏损26美仙。过往派息公布日期派息事项派息内容2024/11/12第三季业绩无派息2024/08/07中期业绩无派息2024...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10